IDO and tolerance to tumors
IDO and tolerance to tumors
复制标题
DOI：
10.1016/j.molmed.2003.11.003
复制
发表时间：
2004-01-01
影响因子：
13.6
通讯作者：
Mellor, AL
中科院分区：
文献类型：
--
作者：
Munn, DH;Mellor, AL
肿瘤对肿瘤相关抗原产生一种病理状态的耐受性。发生这种情况的机制在很大程度上仍不清楚。最近的研究表明，造成这种现象的一个机制可能是免疫调节酶吲哚胺2，3-双加氧酶(IDO)进行的色氨酸分解代谢。IDO可以由肿瘤细胞本身表达，我们认为表达IDO的抗原提呈细胞向肿瘤引流淋巴结的募集可能是诱导对肿瘤来源抗原的耐受的另一种有效机制。基于阻断这一途径的治疗策略可能代表着一类新的肿瘤免疫治疗佐剂。
Tumors create a pathological state of tolerance towards tumor-associated antigens. The mechanisms by which this occurs are still largely unknown. Recent studies suggest that one mechanism contributing to this phenomenon could be tryptophan catabolism carried out by the immunoregulatory enzyme indoleamine 2,3-dioxygenase (IDO). IDO can be expressed by tumor cells themselves, and we propose that the recruitment of antigen-presenting cells expressing IDO to tumor-draining lymph nodes might constitute another potent mechanism for inducing tolerance to tumor-derived antigens. Therapeutic strategies based on blocking this pathway might represent a novel class of adjuvants for tumor immunotherapy.